Navigation Links
Stereotaxis Announces Global Initial Training Site at University of Chicago
Date:12/30/2010

ST. LOUIS, Dec. 30, 2010 /PRNewswire/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that starting in 2011, Stereotaxis will utilize the Remote Magnetic Navigation System in the electrophysiology (EP) lab at the University of Chicago Medical Center to train clinicians planning to install Stereotaxis at their own centers.

With adoption of Stereotaxis' Remote Magnetic Navigation System growing steadily, there is significant new demand for training with the system from clinicians worldwide. The Heart Rhythm Center at the University of Chicago (UCMC) is a world-leader in the care of patients with irregular heartbeats.

"The Heart Rhythm Center at the University of Chicago is one of the busiest university-based interventional programs in the greater Chicago area, providing the latest in diagnostic and treatment modalities," said Dr. Martin Burke, Acting Chief of Cardiology. "With Stereotaxis, we have the ability to care for people with the most complex irregular heartbeats."

This arrangement between UCMC and Stereotaxis creates a unique opportunity for electrophysiologists and other interventionalists who need training in magnetic navigation. UCMC will dedicate its Stereotaxis lab for training with phantom models for discrete periods, giving the Stereotaxis Clinical Training Directors the ability to provide guidance free from the distractions that are common when clinicians engage in training in their own facilities.

"Our experience shows that a well-trained EP clinical team adopts magnetic navigation much more rapidly in the year following the system's installation," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. "So we are focused on developing our clinical training programs as a key business strategy. With our recently launched Odyssey Interventional Network, the Global Initial Training Site demonstrates Stereotaxis' commitment to enhancing the standard of interventional care with innovative education and training solutions. We are excited and grateful to be working with Dr. Burke on this important venture."

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global  economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Completes $40 Million Credit Facility
2. Stereotaxis Announces Public Offering of Common Stock
3. Stereotaxis Receives Commitment to Increase and Extend Credit Facility
4. Stereotaxis Awarded $1.5 Million in Grants under the Qualifying Therapeutic Discovery Project Program
5. Stereotaxis Reports Third Quarter Financial Results
6. Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations
7. Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call
8. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
9. Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year
10. Stereotaxis to Present at the JMP Securities Healthcare Conference
11. Stereotaxis Achieves Intellectual Property Milestone With 100th U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):